Aethlon Medical Stock Dives 42% Amid S-1/A Filing and Hemopurifier Trial Expansion
By ATTN Desk · Editorial oversight: Sean Han
Aethlon Medical Inc. (NASDAQ: AEMD)
Introduction
Aethlon Medical Inc., founded in 1999 and headquartered in San Diego, California, develops immunotherapeutic devices aimed at enhancing the body’s natural defenses against cancer and viral infections. Its lead product, the Aethlon Hemopurifier®, is a lectin-based extracorporeal device designed to remove cancer-promoting exosomes and circulating pathogens. In February 2024, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation for the Hemopurifier® for certain advanced or metastatic cancers and viral infections not addressed by approved therapies.
Corporate Structure
With 11–50 employees, Aethlon operates under a management team led by Chief Executive Officer James Frakes and Chief Medical Officer Steven LaRosa. The company provides updates to its investors through email alerts and maintains communications with stakeholders. Clinical trials are conducted in collaboration with hospitals and contract research organizations, including Royal Adelaide Hospital in Australia and ReSQ Clinical Research.
Hemopurifier by Harper Sunday
Recent Developments and News
On October 30, 2024, Mr. Frakes and Dr. LaRosa presented an overview of the Hemopurifier® at the Virtual Emerging Growth Conference, discussing trial design and enrollment progress. In early 2025, Aethlon initiated a safety, feasibility and dose-finding study of the Hemopurifier® combined with PD-1 inhibitors (pembrolizumab or nivolumab) in patients with solid tumors in Australia. On August 21, 2025, the company filed a Form 8-K, which disclosed ongoing trial milestones and operational updates. Eight days later, on August 29, 2025, Aethlon submitted an amended S-1 registration (S-1/A) with the SEC, detailing planned use of proceeds and updated financial statements ahead of anticipated financing rounds.
Financial and Strategic Analysis
As of September 4, 2025, AEMD shares traded at $0.78, reflecting a decrease of 42.22% for the trading day, with a volume of 431,148 shares. Key metrics are summarized below:
| Metric | Value |
|---|---|
| Share Price | $0.78 (−42.22% on 2025-09-04) |
| 52-Week Range | $1.08 – $8.48 |
| Market Capitalization | $4.13 M |
| Total Cash (most recent quarter) | $3.77 M |
| Net Income (TTM) | −$12.58 M |
| Return on Assets (TTM) | −63.64% |
| Return on Equity (TTM) | −207.29% |
| Total Debt/Equity (most recent quarter) | 20.06% |
| Levered Free Cash Flow (TTM) | −$5.09 M |
The company has not reported revenue from device sales and relies on cash and equity financing to support its research and development and clinical operations. The August 2025 S-1/A filing indicates an intent for a capital raise to extend its cash runway during key trial milestones.
Market Position and Industry Context
Aethlon competes in the medical device sector alongside developers of immunotherapy and extracorporeal filtration technologies. Its proprietary approach focuses on exosome and virus removal, addressing two specific indications: oncology patients who do not respond to standard-of-care therapies and individuals infected with high-risk viruses. The Breakthrough Device designations could enhance its regulatory profile and potentially expedite future approvals. However, the competitive landscape includes established entities in immuno-oncology, sepsis management, and viral therapeutics, necessitating clear evidence of clinical benefits and the formation of strategic partnerships.
TL;DR
Aethlon Medical is advancing its Hemopurifier® through a Phase 1 safety and dose-finding trial in Australia. After filing a Form 8-K on August 21, 2025, and an amended S-1 on August 29, 2025, the company is preparing for a financing round to support ongoing clinical development. Investors are advised to monitor upcoming cohort expansions and interim safety data as important indicators.